TIDMSN.
Smith & Nephew Plc
07 February 2018
Smith & Nephew announces European launch of new PICO(TM) 7
Single Use Negative Pressure Wound Therapy System
7 February 2018
Smith & Nephew (LSE: SN, NYSE: SNN), the global medical
technology business, is pleased to announce the European launch of
the new PICO 7 Single Use Negative Pressure Wound Therapy System
(sNPWT).
PICO 7 delivers a number of enhancements which benefit both the
clinical effectiveness and patient experience.
Clinically PICO 7 delivers a more efficient vacuum and superior
leak management(1) , designed to support improved application on
anatomically challenging areas where it is traditionally more
difficult to achieve and maintain a seal. It also includes an
industry-first dressing-full indicator for sNPWT devices, which is
intended to reduce unnecessary dressing changes and wastage.
For the patient, PICO 7 is more than 25% quieter than the
previous version(2) making it less intrusive, of particular value
when the patient is outside the home or sleeping. There is also a
new user interface to simplify patient operation and a belt clip to
improve portability.
Dr Theresa Hurd, RN, MScN, PhD said "Having tried PICO 7 I can
confirm that it has real clinical, economic and patient benefits.
With the new PICO 7 system I can be confident that we will
experience fewer leaks and can hence reduce the number of nurse
interventions, reducing costs and improving care."
PICO 7 is designed for patients at risk of poor healing, and has
been shown to help minimise the failures of healing that may lead
to infection and/or dehiscence(3) . It is suitable for use in both
a hospital and community setting and approved for a number of
indications, including surgically closed incision sites. A recently
published meta-analysis, demonstrated the efficacy of PICO used
prophylactically for SSI reduction in closed surgical incisions
compared with standard care(3) .
"With PICO we revolutionised the use of negative pressure wound
therapy, making a treatment previously only available in a hospital
inpatient setting available to outpatients in a clinical and cost
effective portable solution," said Paolo Di Vincenzo, Smith &
Nephew's SVP of Advanced Wound Management. "With PICO 7 we have
delivered significant design improvements that contribute to
improved patient outcomes, patient management and HCP efficiency,
keeping Smith & Nephew at the forefront of delivering
pioneering portable negative pressure solutions."
It was confirmed that PICO 7 met all relevant European
requirements on Wednesday 24th January 2018.
- ends -
Enquiries
Media
Dave Snyder
Smith & Nephew +1 (978) 749-1440
Investors / Analysts
Ingeborg Øie +44 (0)20 7960
Smith & Nephew 2285
References
1. Data on file report. DS.16.352.R Measurement of NPWT device
air leak tolerance - PICO vs PICO II. September 2016.
2. Data on file report. DS.17.592.R.V2 Project Opal Acoustic
testing report. November 2017.
3. Strugala, V. and Martin, R. Meta-analysis of comparative
trials evaluating a prophylactic single-use negative pressure wound
therapy system for the prevention of surgical site complications.
Surgical Infections (2017). DOI 10.1089/sur.2017.156
About Smith & Nephew
Smith & Nephew is a global medical technology business
dedicated to helping healthcare professionals improve people's
lives. With leadership positions in Orthopaedic Reconstruction,
Advanced Wound Management, Sports Medicine and Trauma &
Extremities, Smith & Nephew has more than 15,000 employees and
a presence in more than 100 countries. Annual sales in 2016 were
almost $4.7 billion. Smith & Nephew is a member of the FTSE100
(LSE:SN, NYSE:SNN).
For more information about Smith & Nephew, please visit our
website www.smith-nephew.com, follow @SmithNephewplc on Twitter or
visit SmithNephewplc on Facebook.com.
To learn more about what we do to help reduce the human and
economic cost of wounds, please visit www.closertozero.com.
(Forward-looking Statements)
This document may contain forward-looking statements that may or
may not prove accurate. For example, statements regarding expected
revenue growth and trading margins, market trends and our product
pipeline are forward-looking statements. Phrases such as "aim",
"plan", "intend", "anticipate", "well-placed", "believe",
"estimate", "expect", "target", "consider" and similar expressions
are generally intended to identify forward-looking statements.
Forward-looking statements involve known and unknown risks,
uncertainties and other important factors that could cause actual
results to differ materially from what is expressed or implied by
the statements. For Smith & Nephew, these factors include:
economic and financial conditions in the markets we serve,
especially those affecting health care providers, payers and
customers; price levels for established and innovative medical
devices; developments in medical technology; regulatory approvals,
reimbursement decisions or other government actions; product
defects or recalls or other problems with quality management
systems or failure to comply with related regulations; litigation
relating to patent or other claims; legal compliance risks and
related investigative, remedial or enforcement actions; disruption
to our supply chain or operations or those of our suppliers;
competition for qualified personnel; strategic actions, including
acquisitions and dispositions, our success in performing due
diligence, valuing and integrating acquired businesses; disruption
that may result from transactions or other changes we make in our
business plans or organisation to adapt to market developments; and
numerous other matters that affect us or our markets, including
those of a political, economic, business, competitive or
reputational nature. Please refer to the documents that Smith &
Nephew has filed with the U.S. Securities and Exchange Commission
under the U.S. Securities Exchange Act of 1934, as amended,
including Smith & Nephew's most recent annual report on Form
20-F, for a discussion of certain of these factors. Any
forward-looking statement is based on information available to
Smith & Nephew as of the date of the statement. All written or
oral forward-looking statements attributable to Smith & Nephew
are qualified by this caution. Smith & Nephew does not
undertake any obligation to update or revise any forward-looking
statement to reflect any change in circumstances or in Smith &
Nephew's expectations.
Trademark of Smith & Nephew. Certain marks registered US
Patent and Trademark Office.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAUGUBPPUPRUBM
(END) Dow Jones Newswires
February 07, 2018 04:33 ET (09:33 GMT)
Smith and Nephew (NYSE:SNN)
Historical Stock Chart
From Apr 2024 to May 2024
Smith and Nephew (NYSE:SNN)
Historical Stock Chart
From May 2023 to May 2024